The remarkable secondary analysis from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with ...

A new US study suggests that weight-loss medications like Wegovy and Ozempic may have rare but serious side effects, ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in ...

For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023.

Semaglutide, the mega-seller diabetes and weight-loss drug, can significantly reduce the risk of side effects such as kidney ...

Altimmune, Inc. is a biotech company exploring the potential of pemvidutide, a promising GLP-1 agonist. Click here for my ALT ...

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

South San Francisco, California Saturday, May 18, 2024, 09:00 Hrs [IST] ...